CN108403983B - Stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela - Google Patents
Stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela Download PDFInfo
- Publication number
- CN108403983B CN108403983B CN201810613929.XA CN201810613929A CN108403983B CN 108403983 B CN108403983 B CN 108403983B CN 201810613929 A CN201810613929 A CN 201810613929A CN 108403983 B CN108403983 B CN 108403983B
- Authority
- CN
- China
- Prior art keywords
- time
- astragalus
- root
- rhizoma
- safflower
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 38
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 37
- 239000006187 pill Substances 0.000 title claims abstract description 26
- 208000007536 Thrombosis Diseases 0.000 title claims description 12
- 241000208340 Araliaceae Species 0.000 claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 229940107666 astragalus root Drugs 0.000 claims abstract description 5
- 244000144730 Amygdalus persica Species 0.000 claims description 21
- 241001061264 Astragalus Species 0.000 claims description 21
- 244000020518 Carthamus tinctorius Species 0.000 claims description 21
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 21
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 21
- 241001106477 Paeoniaceae Species 0.000 claims description 21
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 21
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 21
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 21
- 235000006533 astragalus Nutrition 0.000 claims description 21
- 210000004233 talus Anatomy 0.000 claims description 21
- 244000046146 Pueraria lobata Species 0.000 claims description 20
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 241000361919 Metaphire sieboldi Species 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000005498 polishing Methods 0.000 claims description 8
- 241000112528 Ligusticum striatum Species 0.000 claims description 5
- 241000212322 Levisticum officinale Species 0.000 claims description 4
- 239000001645 levisticum officinale Substances 0.000 claims description 4
- 241000489492 Arisaema Species 0.000 claims description 2
- 241000331983 Arisaema consanguineum Species 0.000 claims description 2
- 240000003801 Sigesbeckia orientalis Species 0.000 claims description 2
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000002785 anti-thrombosis Effects 0.000 abstract description 4
- 239000003146 anticoagulant agent Substances 0.000 abstract description 4
- 210000003414 extremity Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 210000003205 muscle Anatomy 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 14
- 206010019468 Hemiplegia Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000034783 hypoesthesia Diseases 0.000 description 10
- 206010008479 Chest Pain Diseases 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 210000001364 upper extremity Anatomy 0.000 description 9
- 208000004044 Hypesthesia Diseases 0.000 description 8
- 208000006011 Stroke Diseases 0.000 description 8
- 231100000862 numbness Toxicity 0.000 description 8
- 206010008190 Cerebrovascular accident Diseases 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 7
- 206010049816 Muscle tightness Diseases 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000011514 reflex Effects 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 206010019452 Hemianopia Diseases 0.000 description 5
- 208000007460 Hemianopsia Diseases 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 201000007201 aphasia Diseases 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 201000004810 Vascular dementia Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 208000007379 Muscle Hypotonia Diseases 0.000 description 3
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000011977 language disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000001308 Fasciculation Diseases 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000003773 Meningism Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001077909 Sigesbeckia Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003388 posterior cerebral artery Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Insects & Arthropods (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a stasis-dissolving antithrombotic pill for treating cerebral infarction sequela, which can effectively solve the problems of treatment medication of cerebral infarction sequela, low cost and good curative effect, and is prepared from the following components in parts by weight: 55-65g of ginseng, 320g of astragalus root 280-.
Description
Technical Field
The invention relates to medicine, in particular to a stasis-dissolving antithrombotic pill (also called stasis-dissolving antithrombotic pill) for treating cerebral infarction sequelae.
Background
Cerebral infarction is one of three diseases threatening human health at present, has high morbidity, high disability rate and high death rate, and seriously threatens the health and life safety of middle-aged and elderly people. After the cerebral infarction is treated, although the life is kept, sequelae are often left, which are called cerebral infarction sequelae, the apoplexy patients account for a certain proportion, and the clinical manifestations are that after one year of cerebral infarction, if symptoms such as hemiplegia, language disorder or facial distortion exist, the sequelae are called cerebral infarction sequelae, and the period is also called a cerebral infarction sequelae period, and compared with a recovery period, the recovery speed and the recovery degree are slower. The cerebral infarction sequela mainly comprises hemiplegia, hemilateral limb disorder, limb numbness, hemianopsia, aphasia, high blood viscosity, arteriosclerosis, apoplexy, coronary heart disease, and other symptoms, such as limb numbness, language disorder, hemiplegia, vascular dementia, palpitation, chest pain, chest distress, etc. Seriously affecting the physical health and life safety of the patient.
Although there are many kinds of drugs for treating sequelae of cerebral infarction at present, their use is not satisfactory for various reasons, and the recovery time of these patients is long, and many patients have influence on the continuity and curative effect of treatment due to the occurrence of gastrointestinal reactions such as fullness in the stomach and anorexia, or due to the fact that the economic expenditure of decoction is large and the patients are hard to bear, or due to the fact that decocting traditional Chinese medicines is troublesome and troublesome. Therefore, how to effectively solve the treatment medication of patients with cerebral infarction sequelae is a technical problem to be solved seriously.
Disclosure of Invention
In view of the above situation, in order to overcome the defects of the prior art, the invention aims to provide a stasis-dissolving antithrombotic pill for treating cerebral infarction sequelae, which can effectively solve the problems of medicament for treating cerebral infarction sequelae, low cost and good curative effect.
The technical scheme of the invention is that the cerebral infarction sequelae are mostly caused by deficiency of qi and blood, phlegm stasis and obstruction of channels and collaterals, so that qi invigorating and blood activating, blood stasis removing and collateral dredging and phlegm removing and resuscitation inducing are adopted as treatment rules during treatment, and accordingly, the blood stasis removing and thrombus preventing pill for treating the cerebral infarction sequelae solves the technical scheme that the blood stasis removing and thrombus preventing pill for treating the cerebral infarction sequelae is prepared from the following components in parts by weight: 55-65g of ginseng, 320g of astragalus root 280-; adding water into the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root, immersing and decocting the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root for three times, wherein the time for the first time is 1.5 hours, and the time for the second time and the third time is 1 hour respectively; mixing the fine powder and the soft extract, making pill, drying at low temperature, and polishing.
The traditional Chinese medicine composition has the advantages of rich raw materials, simple preparation method, easiness in production, low cost, convenience in taking and good curative effect, has the effects of tonifying qi and activating blood, removing blood stasis and dredging collaterals, and removing phlegm and inducing resuscitation, effectively solves the problem of long-time treatment medication of patients with cerebral infarction sequelae, and has remarkable economic and social benefits.
Detailed Description
The following examples are provided to explain the present invention in detail.
In particular, the invention may be embodied as set forth in the following examples.
Example 1
In specific implementation, the stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela comprises the following components in parts by weight: 58-62g of ginseng, 315g of astragalus root 285-; adding water into the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root, immersing and decocting the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root for three times, wherein the time for the first time is 1.5 hours, and the time for the second time and the third time is 1 hour respectively; mixing the fine powder and the soft extract, making pill, drying at low temperature, and polishing.
Example 2
In specific implementation, the stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela comprises the following components in parts by weight: 60g of ginseng, 300g of astragalus, 300g of grassleaf sweelflag rhizome, 150g of earthworm, 150g of ground beeltle, 150g of szechuan lovage rhizome, 150g of salvia miltiorrhiza, 150g of fried peach seed, 100g of safflower, 150g of red paeony root, 400g of kudzuvine root, 120g of tabasheer, 120g of processed arisaema consanguineum, 150g of raw rhizoma typhonii and 300g of siegesbeckia orientalis, wherein the ginseng, the grassleaf sweelflag rhizome, the earthworm, the ground beeltle, the szechuan lovage rhizome and 1/2 the kudzuvine; adding water into the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root, immersing and decocting the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root for three times, wherein the time for the first time is 1.5 hours, and the time for the second time and the third time is 1 hour respectively; mixing the fine powder and the soft extract, making pill, drying at low temperature, and polishing.
Example 3
In specific implementation, the stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela comprises the following components in parts by weight: 60g of ginseng, 310g of astragalus, 290g of rhizoma acori graminei, 160g of earthworm, 140g of ground beeltle, 160g of ligusticum wallichii, 140g of salvia miltiorrhiza, 160g of fried peach kernel, 92g of safflower, 160g of red paeony root, 380g of radix puerariae, 120g of concretio silicea bambusae, 115g of prepared arisaema tuber, 160g of raw rhizoma typhonii and 290g of herba siegesbeckiae, wherein the ginseng, the rhizoma acori graminei, the earthworm, the ground beeltle, the ligusticum wallichii and 1/2 are ground into fine powder which is sieved by a sieve of 80; adding water into the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root, immersing and decocting the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root for three times, wherein the time for the first time is 1.5 hours, and the time for the second time and the third time is 1 hour respectively; mixing the fine powder and the soft extract, making pill, drying at low temperature, and polishing.
In the medicines, ginseng and astragalus are used as monarch medicines for tonifying qi, earthworm, ground beeltle, ligusticum wallichii, peach kernel, safflower, salvia miltiorrhiza and red paeony root are used as ministerial medicines for promoting blood circulation and removing meridian obstruction, rhizoma acori graminei, raw rhizoma typhonii, tabasheer and rhizoma arisaematis are used as adjuvant medicines for dissipating phlegm and inducing resuscitation, and siegesbeckia herb and radix puerariae are used as conductant medicines for dispelling wind and removing meridian obstruction. The medicines are used together to achieve the functions of benefiting qi, activating blood circulation, dispelling wind, dredging collaterals, reducing phlegm and inducing resuscitation, and are effectively used for treating cerebral infarction sequelae including hemiparalysis (hemiplegia), hemilateral limb disorder, limb numbness, hemianopsia, aphasia, hyperviscosity blood, arteriosclerosis, limb numbness, language handicap, hemiplegia, vascular dementia, palpitation, chest pain, chest distress and the like caused by stroke, coronary heart disease and the like. And through tests and clinical application, the method obtains very good beneficial technical effects, and the relevant test data are as follows:
first, criteria for selecting case
The symptoms of hemiplegia, hemiparalysis, numbness of limbs, hemianopsia, aphasia, hyperviscosity blood, arteriosclerosis, apoplexy, coronary heart disease, etc. can be used as the standard of selected cases.
II, diagnosis standard
After cerebral infarction, the patient with symptoms of numbness of limbs, language disorder, hemiplegia, vascular dementia, palpitation, chest pain, chest distress and the like caused by hemiplegia, hemilateral limb disorder, limb numbness, hemianopsia, aphasia, hyperviscosity blood, arteriosclerosis, apoplexy, coronary heart disease and the like can be diagnosed with cerebral infarction sequela through cerebral CT examination and diagnosis.
Third, treatment scheme
The pills are taken 2 times each time and 6g each time after meals for treating patients with confirmed cerebral infarction sequelae, 1 month is a treatment course, and the curative effect is counted after 2 treatment courses. During the treatment, the complications of hypertension, diabetes and the like are strictly controlled, and the physical rehabilitation exercise is strengthened.
Fourth, the evaluation criteria of curative effect
According to the Chinese traditional medicine diagnosis and curative effect evaluation standard of apoplexy in the Taian conference in 1986, the Chinese traditional medicine is divided into five grades. (one) basically curing: score over 24 points (i.e. symptoms basically disappear and life is normal). (II) effect display: the score is increased by more than 10 points (the symptoms are obviously improved, and the life quality is improved). (III) effective: score increased by more than 4 points (reduced symptoms and improved quality of life). (IV) invalidation: score increase was less than 4 points (symptoms did not improve significantly, but did not worsen further). (V) deterioration: aggravated disease or death.
Fifthly, statistical treatment
30 patients with confirmed cerebral infarction sequelae are treated, wherein the age of the patients is 18 men, 12 women, 79 years at maximum, 46 years at minimum and 59 years on average; the shortest disease course is 7 days, the longest disease course is 30 days, and the average disease course is 18 days; all cases were confirmed by brain CT. The medicine comprises 6 cases of cerebral thrombosis, 2 cases of cerebral embolism, 22 cases of lacunar cerebral infarction, 19 cases of hypertension, 8 cases of diabetes and 2 cases of rheumatic heart disease.
According to the treatment scheme, the pills are adopted for treatment, and the statistical treatment result is as follows: 11 cases are basically cured, accounting for 36.7 percent; the effective rate is 13 cases, accounting for 43.3%; 4 cases of effectiveness account for 13.3 percent; ineffective 2 cases, accounting for 6.7%; worsened 0 cases. The total effective rate is 93.3%.
Sixty, typical cases
1. Li Yi, male, 56 years old, with half-month anterior process with right hemiplegia, speech disorder, brain CT as "lacunar cerebral infarction", and stable diagnosis after transfusion. The evidence is as follows: hemiplegia on the right, deficient speech, pale and floating complexion, low voice, dark tongue with white, thick and greasy coating. The pill for removing blood stasis and resisting thrombus is given 6g once and 2 times a day, the spirit is improved after half a month, and the activity of the right limb is improved. After February, the right limb functions obviously improved and the life self-care.
2. Some Liu is in female age of 65 years, and the patient is admitted with the chief complaint of 'speech is adverse and the left limb is adverse for 1 day' and the admission is as follows: the traditional Chinese medicine composition has the advantages of being clear in mind, poor in spirit, headache, bad in speech, bad in left limb movement, choking and coughing of drinking water, dysphoria, nausea, poor appetite, poor sleep, dry stool, and capable of moving in one line every 2 days, and a urinary catheter is kept. Physical examination: the tongue is purple-dark, white, thick and greasy coating, and intermittent pulse. Inspecting a nervous system: the speech is bad, the mouth angle is right-side, the tongue is stretched and the tongue is left-side, and the tongue muscle atrophy and fasciculation are not seen. The muscle strength of the upper and lower limbs of the left limb is 0 grade, and the muscle tension is declined. Muscle strength of the right upper limb is grade 5, and muscle tension is normal. Shallow reflection: normal abdominal wall reflex, normal limb superficial sensation, deep reflex: bilateral biceps brachii and triceps brachii tendon reflexes, bilateral knee tendon reflexes, achilles tendon reflexes without hypersymmetry, left babinski sign (+), and palmar chin reflex (+). Brain membrane stimulation characteristics: and (4) negativity. Auxiliary inspection: flat scanning of the skull by CT: low-density images of right cerebral hemisphere and left cerebellar hemisphere consider multiple cerebral infarction, formation of partial softening focus, and cerebral basilar atherosclerosis. The method comprises the following steps: atrial fibrillation has been known for 13 years. The preparation is orally taken 6g once and 2 times a day. Half a month later, the patient had clear mind, spiritual and clear speech, choking and coughing with drinking water, and had no symptoms of right deviation of mouth angle, left deviation of tongue extending, and atrophy of tongue muscles and fasciculation. Grade 3 muscle strength and hypotonia of the left limb. Grade 5 in the right upper limb, normal muscle tone. After 2 months. The patient has clear mind, good spirit, clear speech, no water drinking and choking cough, 4-grade strong muscle strength of the left limb and hypotonia. Grade 5 in the right upper limb, normal muscle tone. The life is self-care.
3. To treat certain disease, female, age 68, with the symptoms of dizziness, weakness of left limb for 4 days, and aggravation of water and cough for 1 day. "is the admission of chief complaints. Admission symptoms are as follows: mental clarity, poor spirit, dizziness, feeling of the head, blurred vision, choking cough with drinking water, numbness and weakness of the left limbs, palpitation, chest distress, slow reaction, memory loss, poor appetite, poor sleep at night, dry stool and small stool. A dark red tongue with white coating and a wiry pulse. Physical examination: 178/89mmHg, nervous system examination: right handedness, decreased memory and computational power, and better positioning and orientation abilities and comprehension abilities. Speech is adverse. The two pupils are equicircular, the diameter of the pupil is about 3mm, and the optical reflection is sensitive. Bilateral frontal lines are symmetrical, the mouth angle is right-handed, the tongue is extended left-handed, the tongue muscles are not atrophied, and no fascial tremor is seen. Muscle strength of the left upper limb and the lower limb is grade 2, muscle tension is declined, and muscle strength of the right upper limb and the lower limb is grade 5, and muscle tension is normal. The ataxia exercise examination cannot be completed, the left side of the body feels declined, and no obvious abnormality is seen on the right side. Right huffman sign and babensky sign (+). Soft neck, no resistance, signs of meningeal irritation (-). Auxiliary inspection: cranial MRI + MRA: 1. prompting the right part of the brain stem to be subjected to subacute early cerebral infarction; 2. multiple white matter demyelination; 3. mild brain atrophy; 4. brain MRA indicates cerebral arteriosclerosis; the posterior cerebral arteries at the right sides P1 and P3 are narrow at a plurality of cavities. The method comprises the following steps: the history of hypertension is 20 years, and the highest blood pressure is 200/100 mmHg; the history of coronary heart disease and unstable angina pectoris is 5 years. The preparation is orally taken 6g once and 2 times a day. Half a month later, the patient had clear mind, spiritual and clear speech, choking and coughing with drinking water, and had no symptoms of right deviation of mouth angle, left deviation of tongue extending, and atrophy of tongue muscles and fasciculation. Grade 3 muscle strength and hypotonia of the left limb. Grade 5 in the right upper limb, normal muscle tone. After 2 months. The patient has clear mind, good spirit, clear speech, no drinking water and cough, 4 grades of strong muscle force at the proximal end of the upper limb at the left side, 4 grades of muscle force at the distal end and slightly strong muscle tension. The right upper and lower limbs have muscle strength of grade 5, and the muscle tension is normal. The life is self-care.
Seven, conclusion
Years of clinical practice, treatment and observation prove that the apoplexy is the syndrome of deficiency in origin and excess in superficiality, which is the deficiency of original qi and the deficiency of liver and kidney; the indications are wind, phlegm and blood stasis blockage, particularly in the convalescent period, the wind, phlegm and blood stasis flow through channels and collaterals, blood vessel blockage, meridian obstruction, qi failure and blood circulation failure, and the symptoms are mostly manifested as weak limbs and weakness and the like, the treatment principles of invigorating qi and activating blood, removing blood stasis and dredging collaterals, and removing phlegm and inducing resuscitation are adopted, so according to the traditional Chinese medicine principle and the monarch, minister, assistant and guide formula principle, the traditional Chinese medicine components and the dosage provided by the invention are combined to achieve the effects of invigorating qi and activating blood, removing blood stasis and dredging collaterals, and removing phlegm and inducing resuscitation, are effectively used for treating the symptoms caused by cerebral infarction, such as hemiplegia (hemiplegia), hemilateral limb disorder, limb numbness, hemianopia, aphasia, hyperviscosity, arteriosclerosis, apoplexy, coronary heart disease and the like, and the sequelae of limb numbness, language, hemiplegia, vascular dementia, palpitation, chest pain, chest distress and the curative effect is as high as 93 percent, the medicine is safe to take, can be taken for a long time, has no adverse reaction, is an innovation on the medicine for treating the cerebral infarction sequela, and has obvious economic and social benefits.
Claims (4)
1. The stasis-removing and thrombus-resisting pill for treating the cerebral infarction sequela is characterized by comprising the following components in parts by weight: 55-65g of ginseng, 320g of astragalus root 280-; adding water into the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root, immersing and decocting the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root for three times, wherein the time for the first time is 1.5 hours, and the time for the second time and the third time is 1 hour respectively; mixing the fine powder and the soft extract, making pill, drying at low temperature, and polishing.
2. The stasis-removing and thrombus-resisting pill for treating the sequelae of cerebral infarction according to claim 1, which is characterized by comprising by weight: 58-62g of ginseng, 315g of astragalus root 285-; adding water into the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root, immersing and decocting the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root for three times, wherein the time for the first time is 1.5 hours, and the time for the second time and the third time is 1 hour respectively; mixing the fine powder and the soft extract, making pill, drying at low temperature, and polishing.
3. The stasis-removing and thrombus-resisting pill for treating the sequelae of cerebral infarction according to claim 1, which is characterized by comprising by weight: 60g of ginseng, 300g of astragalus, 300g of grassleaf sweelflag rhizome, 150g of earthworm, 150g of ground beeltle, 150g of szechuan lovage rhizome, 150g of salvia miltiorrhiza, 150g of fried peach seed, 100g of safflower, 150g of red paeony root, 400g of kudzuvine root, 120g of tabasheer, 120g of processed arisaema consanguineum, 150g of raw rhizoma typhonii and 300g of siegesbeckia orientalis, wherein the ginseng, the grassleaf sweelflag rhizome, the earthworm, the ground beeltle, the szechuan lovage rhizome and 1/2 the kudzuvine; adding water into the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root, immersing and decocting the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root for three times, wherein the time for the first time is 1.5 hours, and the time for the second time and the third time is 1 hour respectively; mixing the fine powder and the soft extract, making pill, drying at low temperature, and polishing.
4. The stasis-removing and thrombus-resisting pill for treating the sequelae of cerebral infarction according to claim 1, which is characterized by comprising by weight: 60g of ginseng, 310g of astragalus, 290g of rhizoma acori graminei, 160g of earthworm, 140g of ground beeltle, 160g of ligusticum wallichii, 140g of salvia miltiorrhiza, 160g of fried peach kernel, 92g of safflower, 160g of red paeony root, 380g of radix puerariae, 120g of concretio silicea bambusae, 115g of prepared arisaema tuber, 160g of raw rhizoma typhonii and 290g of herba siegesbeckiae, wherein the ginseng, the rhizoma acori graminei, the earthworm, the ground beeltle, the ligusticum wallichii and 1/2 are ground into fine powder which is sieved by a sieve of 80; adding water into the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root, immersing and decocting the rest of kudzuvine root, astragalus, herba siegesbeckiae, rhizoma typhonii, peach kernel, safflower, tabasheer, rhizoma arisaematis, salvia miltiorrhiza and red paeony root for three times, wherein the time for the first time is 1.5 hours, and the time for the second time and the third time is 1 hour respectively; mixing the fine powder and the soft extract, making pill, drying at low temperature, and polishing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810613929.XA CN108403983B (en) | 2018-06-14 | 2018-06-14 | Stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810613929.XA CN108403983B (en) | 2018-06-14 | 2018-06-14 | Stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108403983A CN108403983A (en) | 2018-08-17 |
| CN108403983B true CN108403983B (en) | 2021-03-12 |
Family
ID=63141768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810613929.XA Expired - Fee Related CN108403983B (en) | 2018-06-14 | 2018-06-14 | Stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108403983B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115518140A (en) * | 2022-10-22 | 2022-12-27 | 王可兴 | Traditional Chinese medicine composition for treating apoplexy sequela and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512521A (en) * | 2011-12-16 | 2012-06-27 | 商洛学院 | Traditional Chinese medicine composition for treating apoplexy sequela |
| CN107115428A (en) * | 2017-05-15 | 2017-09-01 | 玉林市中医医院 | It is a kind of to treat Chinese medicine composition of apoplexy and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612274A (en) * | 2008-06-27 | 2009-12-30 | 赵爱红 | Health-care soup for treating myocardial infarction |
-
2018
- 2018-06-14 CN CN201810613929.XA patent/CN108403983B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512521A (en) * | 2011-12-16 | 2012-06-27 | 商洛学院 | Traditional Chinese medicine composition for treating apoplexy sequela |
| CN107115428A (en) * | 2017-05-15 | 2017-09-01 | 玉林市中医医院 | It is a kind of to treat Chinese medicine composition of apoplexy and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 基于数据挖掘的中风后遗症方药运用规律研究;朱昌华;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20160615(第6期);E056-746 * |
| 补阳还五汤及其加减方治疗脑梗死的临床研究进展;董征亮;《中国当代医药》;20130331;第20卷(第9期);24-25、27 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108403983A (en) | 2018-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520366B (en) | Be used for the treatment of the Chinese medicine of spastic hemiplegia after stroke | |
| CN108403983B (en) | Stasis-removing and thrombus-resisting pill for treating cerebral infarction sequela | |
| CN101062362A (en) | Chinese traditional medicine agent for treating apoplectic hemiplegia and the sequela thereof | |
| CN102600434B (en) | Compound mixture for curing cervical vertigo | |
| Zhao et al. | Therapeutic efficacy of swallowing neuromuscular electrical stimulation combined with acupuncture for post-stroke dysphagia | |
| CN104056080A (en) | Traditional Chinese medicine composition for treating cerebral thrombosis sequelae | |
| Khan et al. | Ayurveda and Yoga management of chronic alcoholism sequelae-A case report | |
| CN107961342A (en) | A kind of Chinese medicine composition for treating hemiplegia and preparation method thereof | |
| Qaiyyum et al. | MANAGEMENT OF FACIAL PALSY (LAQWA) THROUGH UNANI MEDICINE: A CASE SERIES | |
| CN102940852B (en) | Traditional Chinese machine preparation for treating pseudobulbar paralysis | |
| CN103505591B (en) | A kind of Chinese medicine and preparation for the treatment of post-stroke constipation | |
| Zhou | Curative Effect of Tongyu Decoction on Neurological Deficit and Rehabilitation Effect of Patients with Cerebral Hemorrhage in Recovery Period | |
| CN112370493A (en) | Traditional Chinese medicine pill for treating ascites due to cirrhosis | |
| Qaiyyum et al. | EFFICACY OF A UNANI REGIMEN IN THE TREATMENT OF FALIJ-E-NISFI (HEMIPLEGIA): CASE SERIES | |
| CN112263662A (en) | Chinese medicinal compound granule for treating apoplexy and preparation method thereof | |
| Li et al. | Guidance on home rehabilitation in Chinese and Western medicine to prevent the relapse of novel coronavirus disease-19 pneumonia after recovery | |
| CN115227788A (en) | Traditional Chinese medicine composition for treating blood stasis type diseases, traditional Chinese medicine preparation and preparation method thereof | |
| CN105232744A (en) | Traditional Chinese medicine composition for treating lumbago | |
| CN104958504A (en) | Traditional Chinese medicine composition for preventing and treating sub-health and preparation method of traditional Chinese medicine composition | |
| CN118750550A (en) | Traditional Chinese medicine composition for treating traumatic chest and hypochondrium pain and application thereof | |
| Fazil et al. | QAI (EMESIS): FROM ANCIENT TO MODERN ERA AND ITS THERAPEUTIC EFFICACY IN VARIOUS DISORDERS | |
| CN117138001A (en) | Preparation method of hot compress ointment for treating rheumatoid disease | |
| CN103798792A (en) | Healthcare biological preparation | |
| CN115252751A (en) | Coix seed dampness clearing composition and preparation method thereof | |
| Shanyi | Massage treatment for pediatric allergic rhinitis 1a typical case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210312 |